Investigating how human antibodies affect enterovirus D68 infections
Human antibody modification of enterovirus D68 infection
This study is looking at how a virus called enterovirus D68 might lead to a serious condition called acute flaccid myelitis in kids, and it aims to find out how our body's defenses can help fight this virus to develop better treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11094865 on NIH RePORTER |
What this research studies
This research focuses on understanding the relationship between enterovirus D68 (EV-D68) and acute flaccid myelitis (AFM), a serious illness that primarily affects children. The project aims to explore how human antibodies can modify the effects of EV-D68, which is known to cause respiratory infections and has been linked to neurological complications. The principal investigator will utilize both animal models and human tissue samples to study the virus's pathogenesis and the immune response. This comprehensive approach will help identify potential therapeutic strategies to combat EV-D68 infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adults who have experienced enterovirus D68 infections or are at risk for acute flaccid myelitis.
Not a fit: Patients who have not been exposed to enterovirus D68 or do not have a history of acute flaccid myelitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune response against enterovirus D68, potentially reducing the incidence of acute flaccid myelitis in affected populations.
How similar studies have performed: Previous research has shown promise in understanding the immune response to enteroviruses, but this specific approach to studying EV-D68 and its effects on AFM is relatively novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Vogt, Matthew R — Univ of North Carolina Chapel Hill
- Study coordinator: Vogt, Matthew R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.